Rochester, NY, July 18, 2023 – iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research. This hire demonstrates iuvo’s ongoing commitment to serving our clients, delivering differentiated expertise across our service offerings, and continued investment in the clinical research business to support the company’s growth trajectory.
Powers is an experienced clinical research executive who brings over twenty years of diverse experience to this role. She has had roles with Sponsors and Service providers alike, which will immediately add value to our team and our clients. Powers will lead the team at iuvo’s clinical research subsidary Oculos, and be responsible for the overall operation and performance of that business, including Clinical Operations, Biostatistics, Data Management, Medical / Safety, Project Management, Medical Writing, Site Development / Optimization, and Regulatory Compliance. Powers holds a BA University of Texas at Arlington and a Master of Science in Jurisprudence with a concentration in Pharmaceutical and Medical Device Law and Compliance from Seton Hall Law School. She brings a wealth of experience in drug development and was most recently the VP of Clinical Program Operations at Reata Pharmaceuticals.
“The industry needs service partners that faithfully operationalize studies with the kind of prowess and tenacity that provides sponsors with the quickest possible answers to questions being asked in their clinical protocols,” Powers said. The iuvo/Oculos team has a proven track record of serving clients in this way, and I am truly excited to join this team, to contribute to the diversification of our service offering, and to support the strategic plan to continue to grow the business.”
Daniel Spasic, Board Chair of iuvo BioScience, said, “We are excited to welcome Lacey to the iuvo family and our clinical development organization. We’ve seen a very strong back-log- and pipeline buildup in this business. Lacey will be instrumental in ensuring continued growth and operational excellence across our ophthalmology studies. This important recruitment of Lacey completes the Executive Committee, with all members in place. We can now increase our efforts and focus on the longer-term strategic roadmap, resulting in better serving our customers and employees.”
CEO Ben Burton commented, “Hiring Lacey could not have come at a better time for our business. Her experience with sponsor companies as well as service organizations brings a depth of knowledge and understanding of the clinical research space that will immediately add value for our clients and to our expanding team. I look forward to working with Lacey as a member of our executive committee as we forge ahead with our growth strategy. We are excited to have Lacey onboard.”
About iuvo BioScience
Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company’s facility features laboratories for analytical chemistry, formulation, microbiology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company’s Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Follow iuvo on LinkedIn for additional information.
